Yu Cui

Yu Cui

Auto-generated profile, based on publicly available information

Yu Cui

Shantou University Medical College

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2025 in Computational Biology and Chemistry
Verified
Journal Article
Closed access
YCYu Cui
Yu Cui
YCYanzhu Chen
Yanzhu Chen
MHMengting Hu
Mengting Hu
HZHe Zhou
He Zhou
JGJiarui Guo
Jiarui Guo
STShijie Tang
Shijie Tang

29 January 2024 in medRxiv
Verified
Preprint
Open access
PDF file
YCYu Cui
Yu Cui
MHMengting Hu
Mengting Hu
HZHe Zhou
He Zhou
JGJiarui Guo
Jiarui Guo
QWQijia Wang
Qijia Wang
STShijie Tang
Shijie Tang
Background: Varicose veins (VV) is a common chronic venous disease that is influenced by multiple factors. It affects the quality of life of patients and imposes a huge economic burden on the healthcare system. This study aimed to use integrated analysis methods, including Mendelian randomization analysis, to identify potential pathogenic genes and drug targets for VV treatment. Methods: This study conducted summary-data-based Mendelian randomization (SMR) analysis and colocalization analysis on data collected from genome-wide association studies (GWASs) and cis-expression quantitative trait loci (cis-eQTL) databases. Only genes with PP. H4 > 0.7 were chosen from the significant SMR results. After the above analysis, we screened 12 genes and performed Mendelian Randomization analysis on them. After sensitivity analysis, we identified four genes with potential causal relationships with VV. Finally, we used transcriptome-wide association studies (TWAS) analysis and The Drug-Gene Interaction Database (DGIdb, https://dgidb.org )data to identify and screen the remaining genes and identified four drug targets for the treatment of VV. Results: We identified four genes significantly associated with VV, namely KRTAP5-AS1 (OR = 1.08, 95% CI: 1.05−1.11, p = 1.42e−10) and PLEKHA5 (OR = 1.13, 95% CI: 1.06-1.20, p = 6.90e−5), CBWD1 (OR = 1.05, 95% CI: 1.01-1.11, p = 1.42e−2) and CRIM1 (OR = 0.87, 95% CI: 0.81-0.95, p = 3.67e−3). Increased expression of three genes, namely KRTAP5-AS1 , PLEKHA5 , and CBWD1 , was associated with increased risk of the disease, and increased expression of CRIM1 was associated with decreased risk of the disease. These four genes could be targeted for VV therapy. Conclusion: This study identified four drug targets for potential treatment of VV, and the results may contribute to improving the quality of life of VV patients.

3 May 2024 in medRxiv
Verified
Preprint
Open access
PDF file
YCYu Cui
Yu Cui
JGJiarui Guo
Jiarui Guo
YLYuanxi Lu
Yuanxi Lu
MHMengting Hu
Mengting Hu
HZHe Zhou
He Zhou
STShijie Tang
Shijie Tang
Background: Dorsopathies are a group of musculoskeletal disorders affecting the spinal column and related structures, contributing significantly to global disability rates and healthcare costs. Despite their prevalence, the genetic and biological mechanisms underlying dorsopathies are not fully understood. Method: Summary-data-based Mendelian Randomization (SMR) and colocalization analysis were employed, using data from genome-wide association studies (GWAS) and cis-expression quantitative trait loci (cis-eQTLs) databases. Genes with a colocalization posterior probability (PP.H4) above 0.7 in SMR results were selected for additional analysis. These selected genes underwent MR analysis to examine possible causal connections with dorsopathies, and sensitivity analyses were carried out to ensure robustness. Additionally, two transcriptome-wide association studies (TWAS) were utilized to confirm and screen for potential drug targets. Result: We identified four essential genes linked to dorsopathies: NLRC4 , CGREF1 , KHK , and RNF212 . Mendelian randomization (MR) analysis revealed a potential causal link between these genes and dorsopathies. Elevated transcription levels of NLRC4 , CGREF1 , and KHK correlated with reduced dorsopathies risk, while increased levels of RNF212 were associated with heightened risk of dorsopathies. Regarding methylation sites, an increase in cg04686953 fully mediated the decreased risk of dorsopathies by RNF212 . Similarly, the risk effect of cg26638505 and cg18948125 was entirely mediated by NLRC4 , while CGREF1 predominantly mediated the risk-increasing effect of cg06112415 and the decrease effect of cg22740783 . Conclusion: Dorsopathies were associated with four pivotal genes: NLRC4 , CGREF1 , KHK , and RNF212 . Methylation analysis identified cg04686953 and cg22740783 as protective against dorsopathies risk, while cg26638505 , cg18948125 , and cg06112415 exhibited a risk-increasing impact.